Meningococcus vaccines

A method of eliciting a protective antibody response against Neisseria meningitidis in a mammal comprising administering to the mammal an immunogenic composition comprising a fusion polypeptide, wherein the fusion polypeptide comprises all three of v1, v2 and v3 meningococcal factor H binging proteins (fHbp) in combination with

• (i) a purified, immunogenic meningococcal NHBA polypeptide,
• (ii) a purified, immunogenic meningococcal NadA polypeptide and
• (iii) meningococcal outer membrane vesicles (OMVs) prepared from the meningococcal strain NZ98/254,
• wherein the fHbp fusion polypeptide has an amino acid sequence of formula NH2-A-[-X-L]3-B—COOH, wherein L is an optional linker amino acid sequence, A is an optional N terminal amino acid sequence, and B is an optional C terminal amino acid sequence and wherein X1, X2and X3 are the three of the meningococcal fHbp sequences in the order v2-v3-v1 from the N- to C-terminus,
• wherein the v1 fHbp sequence comprises a sequence with at least 90% sequence identity to SEQ ID NO:
• 7,
• wherein the v2 fHbp sequence comprises a sequence with at least 90% sequence identity to SEQ ID NO:
• 8 and is modified to introduce a stabilizing substitution at position S32that is an amino acid that is not serine, and a stabilizing substitution at position L123 that is an amino acid that is not leucine, and
• wherein the v3 fHbp sequence comprises a sequence with at least 90% sequence identity to SEQ ID NO:
• 9 and is modified to introduce a stabilizing substitution at S32 position that is an amino acid that is not serine, and a stabilizing substitution at L126 that is an amino acid that is not leucine.